Clinical trial · Observational
Biomarkers in Patients With Advanced Rhabdomyosarcoma
Developmental Pathway Drug-Targets in Advanced Rhabdomyosarcomas
NCT01668095CI-TRIAL-00022279completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This research trial studies tumor tissue to identify important proteins and biomarkers from patients with rhabdomyosarcoma that has spread to other places in the body and usually cannot be cured or controlled with treatment. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Rhabdomyosarcoma | Adult Rhabdomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Alveolar Rhabdomyosarcoma | Childhood Alveolar Rhabdomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Childhood Embryonal Rhabdomyosarcoma | Childhood Embryonal Rhabdomyosarcoma | ONTOLOGY_EXACT | 0.98 |
| Previously Treated Childhood Rhabdomyosarcoma | Childhood Rhabdomyosarcoma | CURATED_BROADER | 0.78 |
| Recurrent Adult Soft Tissue Sarcoma | Adult Soft Tissue Sarcoma | CURATED_BROADER | 0.78 |
| Recurrent Childhood Rhabdomyosarcoma | Childhood Rhabdomyosarcoma | CURATED_BROADER | 0.78 |
| Stage III Adult Soft Tissue Sarcoma | Adult Soft Tissue Sarcoma | CURATED_BROADER | 0.78 |
| Stage IV Adult Soft Tissue Sarcoma | Adult Soft Tissue Sarcoma | CURATED_BROADER |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Laboratory Biomarker Analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Ancillary-Correlative (biomarker analysis)
- description
- Immunohistochemistry is performed for each candidate target (Pax3, Pax7, and Patched-1) in each disease (alveolar, embryonal, and anaplastic rhabdomyosarcoma) for tissue microarray analysis.
- interventionNames
- Other: Laboratory Biomarker Analysis
Primary outcomes (1)
- measure
- Prevalence of the candidate target (Pax3, Pax7, or Patched-1), and whether the candidate target is expressed in the tumor vs stroma
- timeFrame
- 1 month
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * 8 tissue microarrays (TMA) slides of the following diseases available: * Alveolar rhabdomyosarcoma * Embryonal rhabdomyosarcoma * Anaplastic rhabdomyosarcoma
References
Publications (0)
Data not yet available
No reference posted for this study.